Physician profile
Blake P Melling
NPI 1487605366
$2,633.95
in general payments reported to CMS, 2019-2025
21 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $296 · 2021: $369 · 2022: $311 · 2023: $282 · 2024: $403 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.01 |
| Education | $232.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $766.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $740.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $180.19 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $113.33 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $110.82 | 2019-2025 | Farxiga |
| Pfizer INC. | $88.73 | 2019-2023 | |
| Lilly USA, LLC | $88.34 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $77.56 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $50.41 | 2020-2023 | |
| Astellas Pharma US INC | $39.82 | 2019 | |
| Amarin Pharma, INC. | $34.15 | 2020 | |
| Inogen, INC. | $33.82 | 2022-2023 | Inogen At Home Stationary Concentrator |
| E.R. Squibb & Sons, L.L.C. | $32.46 | 2022-2023 | Eliquis |
| Esperion Therapeutics, INC. | $29.63 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.42 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.63 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $22.35 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $21.29 | 2024 | Voquezna |
| Genentech USA, INC. | $18.35 | 2019 | |
| Merck Sharp & Dohme LLC | $16.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Melling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.